CREBRF and type 2 diabetes mellitus: This prospective, longitudinal study will follow women from early pregnancy (<14 weeks gestation) to 18 months postpartum, using gold-standard measures of glycemic control to explore pregnancy-related outcomes associated with the CREBRF variant, as well as its mechanisms of action and role in development of T2DM postpartum.